EN
Turkish Ambassador to China Visits SINOVAC in Beijing
Ambassador Musa and SINOVAC Chairman Explore Continued Investment and Cooperation
On November 8, Dr. Ismail Hak Musa, Turkish Ambassador to China, visited Sinovac Biotech Ltd. ("SINOVAC" or the "Company") in Beijing to meet with Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC. The two parties explored opportunities for SINOVAC's further investment and collaboration in Türkiye following the recent inauguration of KeyVac, a SINOVAC joint venture in Ankara that significantly boosts local vaccine production capacity.
Ambassador Musa advocated for continued SINOVAC investments, while Mr. Yin underscored how the Company's commitment to expanding its presence and operations, as well as expressed his expectation on gaining more support from the Turkish government.
During his visit, Ambassador Musa toured SINOVAC's state-of-the-art COVID-19 vaccine production area with Ms. Helen Yang, Chief Business Officer of SINOVAC, for additional insights into the Company's vaccine development and production.
The meeting focused on SINOVAC's deepening engagement with the Turkish government, following President Recep Tayyip Erdoğan's attendance at the inauguration ceremony of KeyVac's vaccine production center, on October 31. There, the president emphasized the strategic importance of local vaccine production after the COVID-19 pandemic. With KeyVac's added capabilities, Türkiye can produce the hepatitis A vaccine to high standards domestically he said, adding that the plant benefits not only the city of Ankara, but all of Türkiye and its people.
KeyVac, firstly broke ground in November 2021, a vaccine company with the production capacity of 30 million doses per year. Leveraging SINOVAC's cutting-edge technology, KeyVac will develop, produce, and supply vaccines that meet Türkiye's local immunization plan, beginning with the hepatitis A vaccine. KeyVac obtained Good Manufacturing Practice (GMP) certification for producing hepatitis A vaccines in October 2023.
SINOVAC has long served as a key ally in Türkiye's national healthcare efforts, supplying the country with millions of doses of its vaccines and supporting local communities in the fight against infectious diseases, such as varicella and COVID-19. During the pandemic, SINOVAC's joint research with Turkish scientists on the COVID-19 inactivated vaccine was published in the world-leading academic journal The Lancet and played an important role providing crucial scientific evidence for the vaccine’s global deployment. This scientific partnership has fostered innovation and earned trust for SINOVAC’s mission to supply vaccines to eliminate human diseases.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.